Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8160391 | 0.84 | KDM4E (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1219299 | 0.84 | KDM4E (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3973 | 0.76 | — | — | |
| SCHEMBL29539234 | 0.69 | CCR1 (0.46) | HTR7HTR1ADRD2HTR2AGRIN2D | |
| SCHEMBL229994 | 0.69 | CCR1 (0.46) | HTR7HTR1ADRD2HTR2AGRIN2D | |
| SCHEMBL8155898 | 0.69 | BTK (0.40) | ALDH1A1HPGDALOX5GRM5 | |
| SCHEMBL8155129 | 0.68 | TSHR (0.44) | ALDH1A1HPGDGRM5 | |
| SCHEMBL955795 | 0.68 | CCR1 (0.52) | GRIN2BALDH1A1HPGDGRM5 | |
| SCHEMBL31354842 | 0.67 | CCR1 (0.46) | HTR7HTR1ADRD2HTR2AGRIN2D | |
| SCHEMBL700152 | 0.67 | CCR1 (0.46) | HTR7HTR1ADRD2HTR2AGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5861140-A | Tripodal paramagnetic contrast agents for MR imaging | HOECHST CELANESE CORP. (US) | 1999-01-19 | — | — | US | claimed |
| US-5861138-A | Ligands for MRI contrast agent | HOECHST CELANESE CORP. (US) | 1999-01-19 | — | — | US | claimed |
| WO-1998022148-A1 | MRI CONTRAST AGENTS AND LIGANDS | WASHINGTON UNIVERSITY (US) | 1998-05-28 | — | — | WO | claimed |
| US-8617723-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| WO-2011066898-A1 | ELECTRONIC DEVICE CONTAINING METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-06-09 | — | — | WO | disclosed |
| US-20110012100-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2254896-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100227978-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-7728137-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| WO-2009118087-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | WO | disclosed |
| EP-1603923-B9 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2007-10-31 | — | — | EP | disclosed |
| EP-1603923-A1 | METAL COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004081017-A1 | METAL COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-09-23 | — | — | WO | disclosed |
| US-6281303-B1 | TRANSITION METAL COMPLEX | EASTMAN CHEMICAL COMPANY | 2001-08-28 | — | — | US | disclosed |
| US-5861140-A | Tripodal paramagnetic contrast agents for MR imaging | HOECHST CELANESE CORP. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5861138-A | Ligands for MRI contrast agent | HOECHST CELANESE CORP. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5858329-A | MRI diagnostic procedures using tripodal pyridinyl metal complexes | HOECHST CELANESE CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5824288-A | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | HOECHST CELANESE CORPORATION (US) | 1998-10-20 | — | — | US | disclosed |
| US-5820851-A | MAGNETIC RESONANCE IMAGING; RESOLUTION | HOECHST CELANESE CORPORATION (US) | 1998-10-13 | — | — | US | disclosed |
| WO-1998022148-A1 | MRI CONTRAST AGENTS AND LIGANDS | WASHINGTON UNIVERSITY (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227978-A1 | METAL COMPLEXES | AP1M1, SOD1, AP2M1 | HTR7 4647/4885HTR1A 3446/4885DRD2 3076/4885 |
| US-20110012100-A1 | METAL COMPLEXES | AP1M1, AP3M1, SOD1 | HTR7 4447/4885HTR1A 4297/4885DRD2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.